A Study of Evacetrapib in Healthy Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

The purpose of this study is to measure how much of the study drug (evacetrapib) gets into the blood stream and how long it takes the body to get rid of it when given with gemfibrozil. Each participant will receive gemfibrozil alone, evacetrapib alone, and both drugs in combination. There is no washout period between doses. The safety of both of the study drugs given together will be evaluated. Information about any side effects that may occur will also be collected. This study will last approximately 36 days.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years to 65 Years (Adult)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

Healthy participants as determined by medical history and physical examination

Have a body mass index of 18 to 32 kilograms per square meter (kg/m^2)

Exclusion Criteria:

Have known allergies to evacetrapib and gemfibrozil, related compounds or any components of the formulation

Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study

Regularly use known drugs of abuse and/or show positive findings on urinary drug screening